Dalantercept

Drug Profile

Dalantercept

Alternative Names: ACE-041

Latest Information Update: 22 Dec 2015

Price : $50

At a glance

  • Originator Acceleron Pharma
  • Class Antineoplastics; Immunoglobulin fusion proteins
  • Mechanism of Action ACVRL1-protein-antagonists; Angiogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Head and neck cancer; Renal cell carcinoma
  • Phase I/II Hepatocellular carcinoma
  • Phase I Multiple myeloma; Solid tumours

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 04 Nov 2015 Dalantercept receives Fast Track designation for Renal cell carcinoma [SC,Injection] (Combination therapy, Metastatic disease, Second-line therapy or greater) in USA
  • 04 Nov 2015 Interim efficacy data from a phase II trial in Renal cell carcinoma released by Acceleron
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top